Strategic capabilities Position 3PBIOVIAN as a pan-European biologics CDMO with end-to-end services across microbial and mammalian expression, viral vectors, cell therapy, plasmid DNA, and fill/finish, enabling quick engagement for biotech startups and mid-market biotechs seeking single-source manufacturing and scale-up.

Recent biosimilar focus Highlight the development of a biosimilar monoclonal antibody for oncology in collaboration with a regional institute, signaling competency in competitive biologics programs and potential partnerships for biosimilar development, technology transfer, and commercial supply.

AAV and advanced therapies Leverage the AAVion Platform launch to target gene therapy developers requiring scalable viral vector manufacturing, analytics, and GMP-grade supply chains, presenting opportunities in preclinical through phase commercial packaging and regulatory readiness.

Strategic collaborations Capitalize on recent mergers and partnerships, awards, and leadership appointments to position as a trusted CDMO with growth trajectory, opening doors to co-development, risk-sharing manufacturing arrangements, and expanded capacity commitments.

Global footprint advantage Emphasize dual-site operations in Pamplona-Noáin and Turku to support diverse supply needs from preclinical to commercial, targeting regional biotechs and emerging players seeking proximity, regulatory alignment, and reliable supply stability.